[PR Newswire] - Cardium Therapeutics today announced the addition of a new weight management product, Appexium™, to Cardium's MedPodium™ product line.  Appexium, a plant-derived non-prescription dietary supplement to be marketed under the trade name Linee™, is designed to manage weight by lowering appetite and hunger in order to reduce caloric intake and facilitate weight loss.  Cardium is planning to formally launch its MedPodium product line in October.  The addition of Appexium represents an important step toward broadening the Company's advanced skin care line to include additional healthy lifestyle medicinals.

[PR Newswire] - Cardium Therapeutics announced today that Christopher J. Reinhard, Cardium's Chairman and Chief Executive Officer will present at the Rodman & Renshaw 12th Annual Healthcare Investment Conference on September 14, 2010 at 4:55 p.m.

[PR Newswire] - Halozyme Therapeutics, Inc. today announced the pricing of its previously announced public offering of 8.3 million shares of its common stock at a price to the public of $7.50 per share.

[Business Wire] - WESTON, Mass.----Biogen Idec Inc. announced today that its presentation at the Stifel Nicolaus 2010 Healthcare Conference will be webcast live on Wednesday, September 15, 2010 at 9:10 a.m.

[PR Newswire] - BioMarin Pharmaceutical Inc. today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Stifel Nicolaus Healthcare Conference in Boston on Friday, September 17, 2010 at 9:10 a.m.

[Business Wire] - BEDFORD, Mass.----Anika Therapeutics, Inc. today announced that Charles Sherwood, president and chief executive officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Wednesday, September 15, 2010 at 9:10 a.m.

[PR Newswire] - Lexicon Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. Arthur T. Sands, president and chief executive officer, will present at the Stifel Nicolaus Healthcare Conference in Boston on Thursday, September 16, 2010 at 9:10 a.m.

[PR Newswire] - Transdel Pharmaceuticals, Inc. reported today that JH Direct has completed their initial product testing of Transdel's anti-cellulite formulation in 24 subjects, which consisted of observing the before and after results of applying the product over a 16 week period.  The excellent results observed during this test have led JH Direct to initiate plans for a final test in approximately 25 subjects to be conducted by a third-party skin research center that will conduct a similar test to the initial test as well as obtain additional measurements over a 12 week period.  JH Direct is planning a commercial launch of the product for the fourth quarter of 2010 or in early 2011 subject to successful completion of this final test.  

[Business Wire] - SOUTH SAN FRANCISCO, Calif.----Exelixis, Inc. announced today that Michael M. Morrissey, PhD, the company’s president and chief executive officer, will present at the following two investor conferences during the month of September 2010: The Stifel Nicolaus 2010 Healthcare Conference in Boston.